Penumbra Inc Stock Price, News & Analysis

Penumbra (NYSE:PEN) announced STORM-PE randomized controlled trial results (Nov 3, 2025) showing that CAVT plus anticoagulation produced significantly greater improvements versus anticoagulation alone in patients with acute intermediate-high risk pulmonary embolism.

Key numeric findings: refined modified Miller score reduction 42.1% vs 15.6% (2.7x; P<0.001), mean heart rate 80.0 vs 86.4 bpm (P=0.022), 90-day six-minute walk 472m vs 376m (P=0.019) and 94% vs 75% predicted walk distance (P=0.022). Safety through 90 days was comparable with no device-related mortality.

Penumbra (NYSE: PEN) reported STORM-PE RCT results (Oct 27, 2025) showing computer assisted vacuum thrombectomy (CAVT) plus anticoagulation was superior to anticoagulation alone for intermediate-high risk pulmonary embolism.

Key results: 100 patients across 22 sites; greater mean reduction in RV/LV ratio at 48 hours (0.52 vs. 0.24; P<0.001); higher positive treatment effect rate (78.3% vs. 51.9%; P=0.011); comparable 7-day major adverse event rates (4.3% vs. 7.5%). Additional STORM-PE data to be presented at VEINS/VIVA (Nov 1-4, 2025).

Penumbra (NYSE: PEN) will host an investor event at the 2025 TCT Conference on October 26, 2025 from 4:00–5:00 PM PT / 7:00–8:00 PM ET to discuss the STORM-PE clinical trial with management and the STORM-PE steering committee. A live webcast will be available on the company's Investors > Events and Presentations page and remain on the site for at least two weeks after the event.

The company also scheduled its Q3 2025 earnings release and conference call for after market close on November 5, 2025, with the call at 4:30 PM ET. The press release with third-quarter financial results will be issued after market close the same day. The conference call dial-in is (888) 596-4144 (conference id: 6572573) and a webcast will be available on the same investor events page for at least two weeks.

Penumbra (NYSE:PEN) and several leading medical organizations announced findings from a comprehensive survey on venous thromboembolism (VTE) care management through their 'Get Out the Clot' campaign. The survey of nearly 270 healthcare professionals revealed significant inconsistencies in blood clot treatment protocols.

Key findings show that only 56% of interventional physicians believe their protocols provide clear direction for pulmonary embolism (PE) risk management, while just 39% feel protocols are clear for deep vein thrombosis (DVT) treatment. Notably, 73% of interventional physicians want expanded use of thrombectomy and computer-assisted vacuum thrombectomy (CAVT) at their hospitals for PE patients, citing benefits like reduced ICU stays (57%) and improved hemodynamics (55%).

The survey also highlighted that more than half of institutions lack formal response teams, and only 35% of physicians report treatment decisions are made by specialty consensus, indicating significant room for improvement in collaborative care approaches.

Penumbra (NYSE: PEN), a leading thrombectomy company, has appointed Shruthi Narayan as its new President, effective September 1, 2025. Narayan, who brings 20 years of medical device industry experience, will report to Adam Elsesser, who continues as chairman and CEO.

Previously serving as president of Penumbra's interventional business, Narayan joined the company in 2013 and has led significant growth in both neuro and vascular franchises. Her experience includes roles at Medtronic and extensive work in engineering, regulatory affairs, and cardiovascular sales.

Penumbra (NYSE: PEN) has announced its upcoming participation in two major healthcare investor conferences. The company will present at the 2025 Wells Fargo Healthcare Conference on September 3, 2025, at 8:45 AM ET, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 1:50 PM ET.

Investors can access the presentation webcasts through Penumbra's website in the "Events and Presentations" section under the "Investors" tab. The recordings will remain available for a minimum of two weeks after each event.

Penumbra (NYSE: PEN) announced its management team will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at 12:30 PM ET/9:30 AM PT.

Investors can access the presentation through a webcast on the company's website under the "Events and Presentations" section of the "Investors" tab at www.penumbrainc.com. The webcast recording will remain available for a minimum of two weeks after the event.

Penumbra (NYSE:PEN), a leading thrombectomy company, reported strong Q2 2025 financial results with revenue of $339.5 million, up 13.4% year-over-year. The company demonstrated robust performance in key segments, with U.S. Thrombectomy revenue reaching $188.5 million, a 22.6% increase, and U.S. VTE revenue growing 42% compared to Q2 2024.

The company achieved net income of $45.3 million with a 13.3% margin and adjusted EBITDA of $61.4 million with an 18.1% margin. Gross profit improved to $224.0 million with a 66.0% margin. Based on strong performance, Penumbra increased its 2025 revenue guidance to $1.355-1.370 billion, representing 13-15% growth over 2024.

Penumbra (NYSE: PEN) has scheduled its second quarter 2025 earnings conference call for July 29, 2025, at 4:30 PM Eastern Time. The company will release its Q2 2025 financial results after market close on the same day.

Investors can access the conference call by dialing (888) 596-4144 with conference ID 6572573, or via webcast through the "Events and Presentations" section on Penumbra's website. The webcast recording will remain available for at least two weeks after the call.